Menu Search
Equities

Aequus Pharmaceuticals Inc

AEQ:DEU

Aequus Pharmaceuticals Inc

Actions
  • Price (EUR)0.019
  • Today's Change0.01 / 111.11%
  • Shares traded0.00
  • 1 Year change-36.67%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Aequus Pharmaceuticals Inc had revenues fall -81.53% from 1.38m to 254.90k, though the company grew net income from a loss of 3.21m to a smaller loss of 2.96m.
Gross margin53.31%
Net profit margin-1,029.67%
Operating margin-1,044.66%
Return on assets-302.43%
Return on equity--
Return on investment--
More ▼

Cash flow in CADView more

In 2023, cash reserves at Aequus Pharmaceuticals Inc fell by 79.62k. Cash Flow from Financing totalled 2.21m or 868.72% of revenues. In addition the company used 2.29m for operations while cash used for investing totalled .
Cash flow per share-0.0206
Price/Cash flow per share--
Book value per share-0.0423
Tangible book value per share-0.0423
More ▼

Balance sheet in CADView more

Aequus Pharmaceuticals Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.0697
Quick ratio0.0431
Total debt/total equity--
Total debt/total capital10.65
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.